Bill
SB 25-066
Requires state agencies to stock opioid overdose reversal drugs and imposes pricing, supply, and reporting rules on providers, aiming to expand access and save lives.
SB 25-066, titled "State Contracts with Opioid Antagonist Businesses", was introduced in the state legislature on January 22, 2025. The bill aimed to establish state contracting requirements for businesses that manufacture or distribute opioid antagonists, which are medications used to reverse opioid overdoses.
The main provisions of SB 25-066 included:
Mandatory Opioid Antagonist Stocking: The bill would have required all state agencies, public schools, and other state-funded entities to stock opioid antagonist medications on-site and train relevant personnel in their use.
State Contracting Requirements: Businesses that provide opioid antagonists to the state would have been required to:
Enforcement and Penalties: The bill proposed fines and other penalties for businesses that failed to comply with the new contracting requirements.
If enacted, SB 25-066 would have significantly expanded access to opioid overdose reversal drugs across the state. This could have helped save lives by making these critical medications more widely available in schools, government offices, and other public settings.
However, the bill faced opposition from some pharmaceutical industry groups who argued the new contracting rules were overly burdensome. The Senate Health & Human Services Committee ultimately decided to postpone the bill indefinitely, effectively killing it for the current legislative session.
SB 25-066 was referred to the Senate Health & Human Services Committee after its introduction. The committee held a public hearing on the bill but ultimately voted to postpone it indefinitely on March 15, 2025, preventing it from advancing further in the legislative process.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
